Abstract:
The present invention relates to genetically modified neural stem cells having cancer stem cell properties, a method for preparing the neural stem cells, and a method for screening anticancer drug candidates using the neural stem cells. According to the present invention, the cancer stem cells having both cancer cell properties and stem cell properties can be easily prepared using a method for introducing y-myc gene and constitutively active form H-Ras gene into the neural stem cells in expressible form. The neural stem cells having cancer stem cell properties in the present invention is very useful for studying the process of cancer genesis and screening the anticancer drug candidates.
Abstract:
본 발명은 암줄기세포 특성을 갖는 유전적으로 변형된 신경줄기세포, 상기 신경줄기세포의 제조방법 및 상기 신경줄기세포를 이용하여 암치료제 후보물질을 스크리닝하는 방법에 관한 것이다. 본 발명에 의하면 v-myc 유전자 및 구성적 활성형 H-Ras 유전자를 신경줄기세포에 발현가능한 형태로 도입시키는 방법에 의해 암세포 및 줄기세포의 특성을 동시에 보유하는 암줄기세포를 용이하게 제조할 수 있다. 본발명의 암줄기세포 특성을 갖는 신경줄기세포는 암 발생 과정의 연구 및 암치료제 후보물질을 스크리닝하는데 매우 유용하다.
Abstract:
The present invention relates to a method for producing a differentiated cell derived from induced a pluripotent stem cell from which an undifferentiated induced pluripotent stem cell (iPS) is eliminated. The method comprises the steps of: preparing a cell sample including undifferentiated iPSs and differentiated cells by differentiating iPSs; and selectively killing undifferentiated iPSs by treating quercetin of Chemical Formula 1 or YM-155 of Chemical Formula 2 on the byproduct of the step (a). According to the present invention, specific differentiated cells are differentiated from iPSs and are cultured in a culture medium for differentiation including quercetin or YM-155, so that only the undifferentiated iPSs can be effectively killed. The method according to the present invention selectively kills only the undifferentiated iPSs that cause the formation of teratomas in order not to affect the differentiated cells at all. Accordingly, the viability and functions of the differentiated cells are maintained so that the possibility of tumor formation can be prevented when the differentiated cells are used clinically as a cell therapy product and so that the stability can be ensured.
Abstract:
PURPOSE: A method for screening an inhibitor of radiation-induced vascular regeneration loss is provided to suppress reduction of vascular regeneration due to cellular senescence and functional damage to EPCs(endothelial progenitor cells). CONSTITUTION: A method for screening an inhibitor of radiation-induced vascular regeneration loss comprises: a step of contacting a sample with a cell containing p53 gene or protein; and a step of measuring the expression level p53 gene, or protein level or activation of p53 protein. The sample is determined as an inhibitor of radiation-induced vascular regeneration loss when the expression level, protein level, or activation is down-regulated. A composition for suppressing radiation-induced vascular regeneration loss contains a material as an active ingredient, which suppresses expression of p53 gene or reduces activation of p53 protein. A pharmaceutical composition for vascular regeneration contains the inhibitor as an active ingredient.
Abstract:
본 발명은 방사선-유도 EPC의 혈관재생성 소실 억제제를 스크리닝하는 방법에 관한 것이다. 보다 상세하게는, (a) p53 유전자 또는 단백질을 포함하는 세포에 분석하고자 하는 시료를 접촉시키는 단계; 및 (b) 상기 p53 유전자의 발현량, p53 단백질의 양 또는 p53 단백질의 활성을 측정하는 단계를 포함하는 방법으로, 상기 p53 유전자의 발현량, p53 단백질의 양 또는 p53 단백질의 활성이 감소-조절(down-regulation)되는 것으로 측정되는 경우에는 상기 시료는 방사선-유도성 혈관재생성 소실 억제제로 판정된다. 본 발명은 방사능 노출로 인해 세포 노화 및 EPCs의 기능 손상되어 혈관 재생이 감소되는 것을 억제할 수 있다.